Spots Global Cancer Trial Database for perjeta
Every month we try and update this database with for perjeta cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers | NCT05738993 | Breast Cancer | BCD-178 Perjeta | 18 Years - 45 Years | Biocad | |
| Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast | NCT03304080 | Breast Neoplasm... Breast Diseases | Anastrozole Palbociclib Trastuzumab Pertuzumab | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers | NCT05738993 | Breast Cancer | BCD-178 Perjeta | 18 Years - 45 Years | Biocad | |
| MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | NCT02213744 | Breast Cancer HER2 Positive B... | MM-302 Gemcitabine Capecitabine Vinorelbine Trastuzumab | 18 Years - | Merrimack Pharmaceuticals | |
| Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer | NCT05802225 | Breast Cancer | BCD-178 Perjeta | 18 Years - 75 Years | Biocad | |
| Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. | NCT03161353 | Breast Cancer | Perjeta Herceptin Docetaxel Carboplatin Letrozole Tamoxifen | 18 Years - | MedSIR | |
| Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast | NCT03304080 | Breast Neoplasm... Breast Diseases | Anastrozole Palbociclib Trastuzumab Pertuzumab | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer | NCT03058939 | Breast Cancer Breast Cancer S... Breast Cancer S... | Paclitaxel Perjeta Herceptin SC Tamoxifen Letrozole LHRH agonist FEC Carboplatin | 18 Years - 70 Years | University of Chicago | |
| Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer | NCT05802225 | Breast Cancer | BCD-178 Perjeta | 18 Years - 75 Years | Biocad | |
| Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast | NCT03304080 | Breast Neoplasm... Breast Diseases | Anastrozole Palbociclib Trastuzumab Pertuzumab | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | NCT02213744 | Breast Cancer HER2 Positive B... | MM-302 Gemcitabine Capecitabine Vinorelbine Trastuzumab | 18 Years - | Merrimack Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
